Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori

NACompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

November 11, 2018

Primary Completion Date

June 10, 2020

Study Completion Date

December 31, 2020

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

Saccharomyces boulardii

500mg bid

DRUG

Esomeprazole

20mg bid

DRUG

Amoxicillin

1.0g bid

DRUG

Clarithromycin

0.5g bid

DRUG

Bismuth potassium citrate

0.22g bid

Trial Locations (1)

430030

Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

Central Hospital of Xiaogan

OTHER

collaborator

Xiaogan First People's Hospital

UNKNOWN

collaborator

Hubei Aerospace Hospital

UNKNOWN

collaborator

The Third People's Hospital of Hubei Province

OTHER

collaborator

Wuhan University

OTHER

collaborator

Anlu Puai Hospital

UNKNOWN

lead

Huazhong University of Science and Technology

OTHER

NCT03688828 - Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori | Biotech Hunter | Biotech Hunter